X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Cadila Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs CADILA HEALTHCARE - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA CADILA HEALTHCARE TORRENT PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 26.6 35.8 74.3% View Chart
P/BV x 6.5 9.2 70.7% View Chart
Dividend Yield % 3.1 0.7 461.9%  

Financials

 TORRENT PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-16
CADILA HEALTHCARE
Mar-16
TORRENT PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,720454 378.5%   
Low Rs1,134305 372.2%   
Sales per share (Unadj.) Rs394.596.1 410.6%  
Earnings per share (Unadj.) Rs101.814.9 684.4%  
Cash flow per share (Unadj.) Rs116.317.8 652.6%  
Dividends per share (Unadj.) Rs40.003.20 1,250.0%  
Dividend yield (eoy) %2.80.8 332.4%  
Book value per share (Unadj.) Rs200.352.3 383.1%  
Shares outstanding (eoy) m169.221,023.74 16.5%   
Bonus/Rights/Conversions -FV5:1-  
Price / Sales ratio x3.63.9 91.6%   
Avg P/E ratio x14.025.5 54.9%  
P/CF ratio (eoy) x12.321.3 57.6%  
Price / Book Value ratio x7.17.3 98.1%  
Dividend payout %39.321.5 182.7%   
Avg Mkt Cap Rs m241,435388,458 62.2%   
No. of employees `00010.915.4 70.5%   
Total wages/salary Rs m8,55913,317 64.3%   
Avg. sales/employee Rs Th6,129.66,371.1 96.2%   
Avg. wages/employee Rs Th785.8862.4 91.1%   
Avg. net profit/employee Rs Th1,581.3986.1 160.4%   
INCOME DATA
Net Sales Rs m66,76498,376 67.9%  
Other income Rs m2,156941 229.2%   
Total revenues Rs m68,92099,317 69.4%   
Gross profit Rs m27,20423,829 114.2%  
Depreciation Rs m2,4613,022 81.4%   
Interest Rs m1,859486 382.4%   
Profit before tax Rs m25,04121,262 117.8%   
Minority Interest Rs m0-300 0.1%   
Prior Period Items Rs m05 0.0%   
Extraordinary Inc (Exp) Rs m-1,403-25 5,611.6%   
Tax Rs m6,4145,716 112.2%   
Profit after tax Rs m17,22415,226 113.1%  
Gross profit margin %40.724.2 168.2%  
Effective tax rate %25.626.9 95.3%   
Net profit margin %25.815.5 166.7%  
BALANCE SHEET DATA
Current assets Rs m46,62244,376 105.1%   
Current liabilities Rs m32,84334,071 96.4%   
Net working cap to sales %20.610.5 197.0%  
Current ratio x1.41.3 109.0%  
Inventory Days Days7454 137.9%  
Debtors Days Days7962 126.7%  
Net fixed assets Rs m39,02947,896 81.5%   
Share capital Rs m8461,024 82.6%   
"Free" reserves Rs m31,40048,746 64.4%   
Net worth Rs m33,89053,519 63.3%   
Long term debt Rs m18,6378,964 207.9%   
Total assets Rs m90,136100,163 90.0%  
Interest coverage x14.544.7 32.3%   
Debt to equity ratio x0.50.2 328.3%  
Sales to assets ratio x0.71.0 75.4%   
Return on assets %21.215.7 135.0%  
Return on equity %50.828.4 178.6%  
Return on capital %48.534.3 141.5%  
Exports to sales %43.345.3 95.7%   
Imports to sales %6.95.9 115.7%   
Exports (fob) Rs m28,93444,537 65.0%   
Imports (cif) Rs m4,5845,838 78.5%   
Fx inflow Rs m29,18544,881 65.0%   
Fx outflow Rs m6,0219,069 66.4%   
Net fx Rs m23,16535,812 64.7%   
CASH FLOW
From Operations Rs m27,13219,938 136.1%  
From Investments Rs m-7,014-9,039 77.6%  
From Financial Activity Rs m-14,352-9,527 150.6%  
Net Cashflow Rs m5,7671,372 420.3%  

Share Holding

Indian Promoters % 71.5 74.8 95.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 8.3 84.6%  
FIIs % 12.6 5.9 213.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 11.0 80.0%  
Shareholders   26,511 44,069 60.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  UNICHEM LAB  ALEMBIC PHARMA  AJANTA PHARMA  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Amid Fed and ECB Minutes, L&T, Power Grid & IOC Among Other Top Stocks to Watch Out Today(Pre-Open)

On Thursday, Indian share markets oscillated between green and red in a broad range throughout the day and ended the session with marginal gains, with Nifty holding 9,900 mark.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Aug 17, 2017 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS